Pemetrexed is a drug owned by Shilpa Medicare Ltd. It is protected by 1 US drug patent filed in 2023 out of which none have expired yet. Based on its patents and exclusivities, its generic launch date is estimated to be Mar 26, 2035. Details of Pemetrexed's patents and their expiration are given in the table below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc). | |||
| US11147817 | Pharmaceutical composition of pemetrexed |
Mar, 2035
(9 years from now) | Active |
A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Pemetrexed's patents.
Latest Legal Activities on Pemetrexed's Patents
Given below is the list of recent legal activities going on the following patents of Pemetrexed.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Recordation of Patent Grant Mailed Critical | 19 Oct, 2021 | US11147817 |
| Patent Issue Date Used in PTA Calculation Critical | 19 Oct, 2021 | US11147817 |
| Email Notification Critical | 30 Sep, 2021 | US11147817 |
| Issue Notification Mailed Critical | 29 Sep, 2021 | US11147817 |
| Dispatch to FDC | 22 Sep, 2021 | US11147817 |
| Application Is Considered Ready for Issue Critical | 22 Sep, 2021 | US11147817 |
| Issue Fee Payment Verified Critical | 20 Sep, 2021 | US11147817 |
| Issue Fee Payment Received Critical | 20 Sep, 2021 | US11147817 |
| Electronic Review Critical | 01 Jul, 2021 | US11147817 |
| Email Notification Critical | 01 Jul, 2021 | US11147817 |
US patents provide insights into the exclusivity only within the United States, but Pemetrexed is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Pemetrexed's family patents as well as insights into ongoing legal events on those patents.
Pemetrexed's Family Patents
Explore Our Curated Drug Screens
Generic Launch
Generic Release Date:
Pemetrexed's generic launch date based on the expiry of its last outstanding patent is estimated to be Mar 26, 2035 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)
Pemetrexed Generics:
There are no approved generic versions for Pemetrexed as of now.
Alternative Brands for Pemetrexed
There are several other brand drugs using the same active ingredient (Pemetrexed Disodium) as Pemetrexed. Given below is the list of those companies and their brand drugs, to help you identify new opportunities, assess competitors, and plan your market strategies more effectively.
| Drug Owner | Drug Name | |
|---|---|---|
| Lilly |
|
About Pemetrexed
Pemetrexed is a drug owned by Shilpa Medicare Ltd. Pemetrexed uses Pemetrexed Disodium as an active ingredient. Pemetrexed was launched by Shilpa in 2023.
Approval Date:
Pemetrexed was approved by FDA for market use on 22 May, 2023.
Active Ingredient:
Pemetrexed uses Pemetrexed Disodium as the active ingredient. Check out other Drugs and Companies using Pemetrexed Disodium ingredient
Dosage:
Pemetrexed is available in solution form for intravenous use. Given below is detailed information on Dosage -
| Strength | Dosage Form | Availability | Application Pathway |
|---|---|---|---|
| EQ 100MG/10ML BASE (10MG/ML) | SOLUTION | Prescription | INTRAVENOUS |
| EQ 1GM/100ML BASE (10MG/ML) | SOLUTION | Prescription | INTRAVENOUS |
| EQ 500MG/50ML BASE (10MG/ML) | SOLUTION | Prescription | INTRAVENOUS |